Dallas, Texas 04/08/2014 (FINANCIALSTRENDS) – Inovio Pharmaceuticals Inc. (NYSEMKT:INO) has declared that post for the new VP for quality would be taken up by E.J. Brandreth.The synthetic vaccine manufacturer is currently busy in the development of INO-5150 vaccine for prostate cancer.
Announcement of New VP
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) had recently announced the name of E.J. Brandreth for the post of Vice President of quality. Brandreth would report to Dr. Niranjan Sardesai, who is the Chief Operating Officer of Inovio Pharmaceuticals Inc. (NYSEMKT:INO). Brandrethhas a proven track record of growth in field of quality for varied pharma companies, making him the first choice for the coveted post of VP of Quality in Inovio Pharmaceuticals Inc. (NYSEMKT:INO). The roles and responsibilities for the new VP would include ensuring that the proper quality and the compliance functions of the company would be strictly adhered to, especially in light of numerous clinical trials taking place which are in varied stages. He would also play an important role in ensuring quality in various operational areas of the company for making the way smoother for the scheduled DNA vaccines as well as immunotherapies.
INO-5150 vaccine in preclinical stage
The $721.23 millionmanufacturer company, which has around 0.3% of insider ownership, is currently busy with the new ‘INO-5150’ vaccine which is for treatment of prostate cancer. The approach for this vaccine is in immunotherapy. But this new vaccine is supposed to have a biological mechanism that is completely different from the existing Provenge vaccine. As of now, the INO-5150 vaccine is in the pre-clinical stageof development.
Industry awards bestowed
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) had been given three different awards by Vaccine Industry Excellence (ViE) awards, during the World Vaccine Congress held during last month in Washington, D.C. they include Best Therapeutic Vaccine, Best Licensing Deal, as well as Best Early Stage Vaccine Biotech.